Email updates

Keep up to date with the latest news and content from BMC Proceedings and BioMed Central.

This article is part of the supplement: International Conference on Prevention & Infection Control (ICPIC 2011)

Open Access Poster presentation

Lupoid cutaneous leishmaniasis in Afghanistan treated with 0.045% DAC N-055

KW Stahl1* and IG Sakhayeee2

  • * Corresponding author: KW Stahl

Author Affiliations

1 Waisenmedizin e. V., Freiburg i. Brsg., Germany

2 Dermatology, Balkh Civil Hospital, Mazar-e-Sharif, Afghanistan

For all author emails, please log on.

BMC Proceedings 2011, 5(Suppl 6):P247  doi:10.1186/1753-6561-5-S6-P247

The electronic version of this article is the complete one and can be found online at: http://www.biomedcentral.com/1753-6561/5/S6/P247


Published:29 June 2011

© 2011 Stahl and Sakhayeee; licensee BioMed Central Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction / objectives

Lupoid leishmaniasis (LCL) is a rare, face disfiguring, treatment resistant complication which has responded to the expensive photodynamic therapy in 5 patients in Iran [ F. Ghaffarifar et al. La Rev. de la Méditerranée orientale Vol. 12 No. 6, 2006]. Here we report 5 cases,- photodocumented as best as we could under the actually disastrous conditions of Afghan Health Care,- treated with 0.045% DAC N-055 [German Drug Codex, 1990], which is split into 1O2 and 2NaClO2 after 360 nm light exposure and reacts as chlorite in iodometry.

Methods

The faces of 5 patients with a CL anamnesis and clinically diagnosed as lupoïd CL were treated daily for the first week with 0.045 % DAC N-055 prepared in basic crème DAC B-20 under occlusive dressings, thereafter the patients were instructed to treat themselves with this hydrophilic crème and were told to show up as outdoor patients at least once per fortnight. Pharmaceutical chlorite, NaClO2 [monograph DAC N-055] is O2 enriched due to its Na2Cl2O6 content, formerly called TCDO, (NaClO2)4·O2, which fights viral, bacterial or parasitic tissue infections and promotes wound granulation even in radiogenic ulcers [http://www-pub.iaea.org/mtcd/publications/pdf/te_1300_web.pdf webcite].

Results

1 patient was lost, 4 patients healed completely without scarring and with excellent cosmetic results (see photos!), 3 within 3 months, 1 after 10 months because of an additional severe eczema. There were no clinical signs of recurrence, one patient was followed for 6 years.

Conclusion

The low treatment costs for such excellent cosmetic results are appropriate for poor Afghan patients.

Disclosure of interest

None declared.